<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820365</url>
  </required_header>
  <id_info>
    <org_study_id>SC12267-4-2008</org_study_id>
    <secondary_id>EudraCT-Number: 2008-005903-25</secondary_id>
    <nct_id>NCT00820365</nct_id>
  </id_info>
  <brief_title>SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease</brief_title>
  <acronym>ENTRANCE</acronym>
  <official_title>Exploratory, Open-label Study to Demonstrate Efficacy, Safety and Tolerability of SC12267 (35 mg) in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4SC AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4SC AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, open-label, uncontrolled, multi-center, 1-arm study conducted at 16&#xD;
      sites in Bulgaria, Germany and Romania.&#xD;
&#xD;
      A total of ca. 30 - 35 patients will receive SC12267 (4SC-101) tablets, 35 mg once daily for&#xD;
      12 weeks. First of all the patients will undergo a screening period of 1 week and a follow-up&#xD;
      visit will be performed 4 weeks after study drug discontinuation or earlier in case of&#xD;
      relapse during follow up. Total study duration will be up to 36 (+2) weeks.&#xD;
&#xD;
      There will be 8 study visits: one screening visit, 6 visits during the treatment period and&#xD;
      one follow-up visit. In addition, four telephone visits will be performed at Week 6, Week 10,&#xD;
      Week 20 (+1) and Week 36 (+2).&#xD;
&#xD;
      The duration of the entire study (first patient in till last patient out) is expected to be&#xD;
      about 13 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of SC12267 (4SC-101) at a dose of 35 mg once daily in patients with Crohn's Disease (CD) or Ulcerative Colitis (UC) after a 12 week therapy as measured by the number of patients with complete or partial response.</measure>
    <time_frame>after a 12 week therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective of this study is to evaluate the safety and tolerability of SC12267 (4SC-101) at a dose of 35 mg once daily in patients with CD or UC and to explore plasma levels (trough values) of SC12267 (4SC-101).</measure>
    <time_frame>after a 12 week therapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Inflammatory Bowel Disease (IBD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC12267 (4SC-101)</intervention_name>
    <description>Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria regarding Crohn´s Disease:&#xD;
&#xD;
          -  Established diagnosis of CD, confirmed by standard criteria (e.g. endoscopy,&#xD;
             ultrasound, X-ray)&#xD;
&#xD;
          -  Patients must be in clinical remission (Crohn's Disease Activity Index [CDAI] &lt;150&#xD;
             points) on steroid therapy for at least 2 weeks&#xD;
&#xD;
          -  Confirmed steroid-dependency of CD: patients who are either&#xD;
&#xD;
               1. unable to taper steroids completely within 3 months of starting steroids, without&#xD;
                  recurrent active disease, or&#xD;
&#xD;
               2. who have a relapse within 2 months of stopping steroids&#xD;
&#xD;
          -  Individual threshold* dose of previous relapses should be equal or less than 20 mg/day&#xD;
             Prednisolone or equivalent steroid dose&#xD;
&#xD;
          -  Patients with stable glucocorticosteroid therapy between 20 and 40 mg/day Prednisolone&#xD;
             or equivalent steroid dose for the previous week&#xD;
&#xD;
        Criteria regarding Ulcerative Colitis:&#xD;
&#xD;
          -  Established diagnosis of UC, confirmed by standard criteria (e.g. endoscopy,&#xD;
             ultrasound, X-ray)&#xD;
&#xD;
          -  Patients must be in clinical remission (Clinical Activity Index [CAI] &lt;4 points) on&#xD;
             steroid therapy for at least 2 weeks&#xD;
&#xD;
          -  Confirmed steroid-dependency of UC: patients who are either&#xD;
&#xD;
               1. unable to taper steroids completely within 3 months of starting steroids, without&#xD;
                  recurrent active disease, or&#xD;
&#xD;
               2. who have a relapse within 2 months of stopping steroids&#xD;
&#xD;
          -  Individual threshold* dose of previous relapses should be equal or less than 20 mg/day&#xD;
             Prednisolone or equivalent steroid dose&#xD;
&#xD;
          -  Patients with stable glucocorticosteroid therapy between 20 and 40 mg/day Prednisolone&#xD;
             or equivalent steroid dose for the previous week&#xD;
&#xD;
        (* The threshold dose is that dose at which the patient experienced the relapses)&#xD;
&#xD;
        Criteria regarding general requirements:&#xD;
&#xD;
          -  Men and women, 18 to 70 years of age&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Negative pregnancy test at screening in females of child-bearing potential&#xD;
&#xD;
          -  Males willing to use condoms or to be sexually abstinent&#xD;
&#xD;
          -  Use of appropriate contraceptive methods for females of childbearing potential one&#xD;
             month before, throughout the course of the study and one month after study&#xD;
             termination. This must be a combination of the following:&#xD;
&#xD;
               1. a highly effective method of first choice = a method with a low failure rate&#xD;
                  (i.e. less than 1% per year) like sexual abstinence, combined oral&#xD;
                  contraceptives, implants, injectables, some Intra Uterine Devices (IUDs),&#xD;
                  vasectomized partner&#xD;
&#xD;
                  together with&#xD;
&#xD;
               2. a method of second choice like condom, diaphragm, or cup pessary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria regarding gastrointestinal conditions:&#xD;
&#xD;
          -  Short bowel syndrome&#xD;
&#xD;
          -  Ileostomy, colostomy or rectal pouch&#xD;
&#xD;
          -  Relapse during screening&#xD;
&#xD;
        Criteria regarding medical history:&#xD;
&#xD;
          -  History of or existence of active tuberculosis&#xD;
&#xD;
          -  History of or existence of urolithiasis&#xD;
&#xD;
          -  History of or existence of human immune deficiency virus (HIV), Hepatitis B or C&#xD;
&#xD;
          -  History of malignancy within the past five years (excluding basal cell carcinoma of&#xD;
             the skin)&#xD;
&#xD;
          -  Previous opportunistic infection&#xD;
&#xD;
          -  History of serious drug sensitivity&#xD;
&#xD;
        Criteria regarding concomitant diseases:&#xD;
&#xD;
          -  Significant cardiac arrhythmia, bradycardia or tachycardia or any other significant&#xD;
             finding in the electrocardiogram (ECG)&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Uncontrolled arterial hypertension&#xD;
&#xD;
          -  Uncontrolled asthma&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Renal insufficiency defined as glomerular filtration rate (GRF) &lt;50 ml/min/1.73 m²&#xD;
             (estimated GRF according to Cockcroft-Gault)&#xD;
&#xD;
          -  Psychiatric illness&#xD;
&#xD;
          -  Known or suspected immunodeficiency&#xD;
&#xD;
          -  Laboratory abnormalities: hemoglobin &lt;8.5 g/dl, white blood cell count &lt;3500/mm³,&#xD;
             platelet count &lt;125 000/mm³, clinically relevant elevation of liver enzymes, serum&#xD;
             creatinine level &gt;=1.4 mg/dl, hematuria (&gt;=10 erythrocytes/field on dipsticks)&#xD;
&#xD;
        Criteria regarding concomitant circumstances:&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  History of alcohol and/or drug dependence&#xD;
&#xD;
          -  Heavy smoking (more than 20 cigarettes per day)&#xD;
&#xD;
          -  Use of prohibited drugs or treatments&#xD;
&#xD;
          -  Patient not able or not willing to follow study procedures due to physical or&#xD;
             psychological limitations or language problems&#xD;
&#xD;
          -  Participation in another investigational drug or vaccine trial within the last three&#xD;
             months or concurrently with this study&#xD;
&#xD;
          -  Vaccination with life attenuated viruses within 4 weeks prior to study start&#xD;
&#xD;
          -  Patient with any medical condition which, in the opinion of the investigator or his&#xD;
             designee, could jeopardize or compromise the ability of the patient to participate in&#xD;
             the trial&#xD;
&#xD;
          -  Patients possibly dependent on the investigator or the sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Herrlinger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Bosch Krankenhaus, Stuttgart, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokuda Hospital Gastroenterology Division Internal Medicine Department</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sv. Ivan Rilski&quot; Gastroenterology Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Tsaritsa Ioanna&quot; - ISUL Gastroenterology Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruhr-Universität Bochum, St. Josef-Hospital, I. Medizinische Klinik</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Gastroenterologie, Hepatologie, Endokrinologie und Klinische Infektiologie</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für chronisch entzündliche Darmerkrankungen</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis Herne</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München II. Medizinische Klinik des Klinikums rechts der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis am Germania-Campus</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elias University Emergency Hospital</name>
      <address>
        <city>Bucuresti</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colentina Clinical Hospital</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Emergency Hospital</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>May 17, 2011</last_update_submitted>
  <last_update_submitted_qc>May 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Bernhard Hauns, Medical Director Oncology</name_title>
    <organization>4SC AG</organization>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease (IBD)</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>SC12267</keyword>
  <keyword>4SC-101</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

